Rheumatoid Arthritis Drugs Market USD 27.26 Billion in 2022

The Rheumatoid Arthritis Drugs market is projected to grow at a rate of 4.00% in terms of value, from USD 27.26 Billion in 2020 to reach USD 37.41 Billion by 2030. Rheumatoid arthritis is a chronic auto-immune disorder that affects joints in the knee, wrists, and fingers, among others, along with extra-articular organs and articular tissues. Roughly, 1.0% of the global population is affected by the disease. Arthritis medications such as Methotrexate play a crucial role as an anti-inflammatory agent in controlling the symptoms and progression of rheumatoid arthritis. Statistics show that out of every 100,000 people, 41 are diagnosed with the disease every year. Women are about 2-3 times more likely to get the disease than men. Hormones in both genders may play a role in either preventing or triggering it.

With no permanent cure for the disease, the goals of the treatment are to decrease inflammation, reduce pain, improve a person’s overall function, and prevent bone deformity. Disease-modifying antirheumatic drugs (DMARDs) find usage to mitigate the progression of the disease. Recent advancements with biosimilars which may be used to treat RA and increase in approvals of the same by regulatory affairs have opened new avenues for the RA Drugs market.

Request a Sample@ https://qyresearchmedical.com/sample/118984

However, expiry of patents of vital drugs may create hindrances in the growth of the market in the forecast period

Drug Class Outlook:

NSAIDs or Non-steroidal Anti-inflammatory Drugs blocks an enzyme that promotes inflammation. It reduces inflammation and helps reduce pain and swelling but is ineffective in reducing joint damage. NSAIDs alone cannot treat the disease and should be taken along with other rheumatoid arthritis medications.

Glucocorticoids a kind of potent anti-inflammatory steroids having the capability to prevent other types of immune system responses and can be taken only through oral route as a pill or by means of an injection. These drugs are found to be beneficial in mitigating symptoms and can even prevent or decrease the rate of joint damage.

Route of Administration Outlook:

Drugs can be administered by various routes such as oral, subcutaneous, and intravenous. Oral Drugs have led to higher prevalence as compared to the others and are forecasted to grow with a CAGR of 4.2% during the forecast period. The oral route of administration is desired over the several other routes of administering drug attributed to the offering of several benefits comprising safety, ease of absorption, no pain during administration, and adaptability to numerous kinds of drugs.

Sales Channel Outlook

The availability of Rheumatoid Arthritis Drugs online has witnessed significant sales owing to the ease of receiving these medicines. Moreover, as the patients are generally old and unable to move a lot, ordering online is more comfortable.

Hospital pharmacies are expected to dominate the market owing to the increase in the rheumatologist consultations in clinics and hospitals. The prolonged use of these medications can lead to drug resistance, which compels the patients to refer to a rheumatologist and follow guided therapies. Moreover, the number of OTC Drugs available for treatment is insufficient, which, in turn, is further propelling the growth of this segment

Regional Outlook

North America is expected to grow at a steady growth due to the increasing prevalence of rheumatoid arthritis and rising awareness about this disorder. Governments of the North American region are investing huge sums in improving the medical and healthcare facilities in the region.

The market in Asia-Pacific is anticipated to witness high growth during the forecast period owing to the increasing healthcare expenditure. Furthermore, the low cost of manufacturing in India and China has resulted in an increase in the production facilities, which attracts pharmaceutical and biotechnological giants to the region.

Europe is forecasted to grow with a CAGR of 4.1% during the forecast period owing to the efforts of the government and private organizations to generate awareness by organizing campaigns and health impediments that are further driving the market.


  • The growing incidence of rheumatoid arthritis and the increase in the geriatric population has propelled the demand for the market. With consistent research, the transition from symptom management to slowing the progression of the disease has further driven market growth.
  • There are different types of over-the-counter and prescription analgesics available, and narcotics are the most potent type of analgesic. Some of the common analgesics are acetaminophen, tramadol, oxycodone, and hydrocodone.
  • Statistics show that out of every 100,000 people, 41 are diagnosed with RA every year. Women are about 2-3 times more likely to get RA than men. Hormones in both genders may play a role in either preventing or triggering it.
  • Side effects associated with the consumption of drugs and the high cost associated with biologics and biosimilars are hindering the growth of the market.
  • Developing nations are making efforts to enhance their healthcare infrastructure to provide medical aid for diseases such as chronic arthritis, which is also encouraging market growth.

Competitive Landscape

Key participants include Amgen Inc., Celgene Corporation, Boehringer Ingelheim GmbH, Johnson & Johnson, Novartis AG, AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, and Merck & Co. Inc., among others.

The players operating in the market have undertaken a number of strategies related to the market in the period 2017-2020. Some of the key highlights are:

  • In December 2019, Amgen Inc. made an announcement about the receiving of approval of the US Food and Drug Administration for Avsola, a biosimilar drug rheumatoid arthritis drug.

Start-up Traction

The industry offers numerous growth opportunities. Thus, a number of startups providing innovative products and technologies have been entering the market. Some of them include Evelo Bosciences, MiroBio, and InnVentis, among others.

Deal Landscape

Mergers and Acquisitions are an integral part of the industry. Along with the companies operating in the market, other key market players have also been entering the industry.

  • In August 2019, Amgen made an announcement about the signing of a deal with Celgene Corporation for the acquisition of the global worldwide rights to an arthritis drug for USD 13.40 billion.

Expert Insights:

Reports and Data forecasts promising developments for increased adoption of rheumatoid arthritis drugs. According to industry experts, corticosteroids and NSAIDs for the treatment of rheumatoid arthritis are garnering significant traction in the market. New companies entering the industry would emphasize designing and developing innovative products, thereby catering to the increasing requirement of end-users.

Segments covered in the report:

This report forecasts revenue growth at a global, regional & country level, and provides an analysis of the industry trends in each of the sub-segments from 2017 to 2027. The scope of the report can be defined as:

For the purpose of this study, Reports and Data have segmented the rheumatoid arthritis drugs market on the basis of drug class, route of administration, sales channel, and region:

Drug Class Outlook (Revenue, USD Million; 2019-2030)

  • Corticosteroids
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Analgesics
  • Other Drugs Classes

Route of Administration Product Type Outlook (Revenue, USD Million; 2019-2030)

  • Oral
  • Subcutaneous
  • Intravenous

Sales Channel Outlook (Revenue, USD Million; 2019-2030)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online

Regional Outlook (Revenue, USD Million; 2019-2030)

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Benelux
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • MEA
    • Saudi Arabia
    • UAE
    • Rest of the Middle East and Africa

Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/118984/1500

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

About Us

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.

For Latest Update Follow Us:

URL – http://www.qyresearchmedical.com/




Leave a Comment

Your email address will not be published. Required fields are marked *